Track 1	Case from the practice of Dr Mary Ann K Allison A 53-year-old woman who, as part of a clinical trial, received dose-dense AC, nanoparticle albumin-bound (nab) paclitaxel and tamoxifen for a 2.2-cm, Grade III, ER-negative, PR-positive, HER2-negative invasive ductal carcinoma with lymphovascular invasion and 1/16 positive nodes. Within a year, she developed a subpectoral mass.
Track 2	Case from the practice of Dr Frederick M Schnell A 58-year-old woman who received CMF in 1988 after a modified radical mastectomy (MRM) for ER-positive, PR-positive, node-negative, invasive breast cancer. Eleven years later, she underwent excision and radiation therapy for a contralateral, 0.8-cm, ER-positive, PR-positive, HER2-negative, node-negative, invasive ductal carcinoma with DCIS. In 2004, she presented with widespread metastatic disease.
Track 3	Case from the practice of Dr Frederick P Smith A 65-year-old woman treated four years ago for a 1.6-cm, ER-positive, PR-positive, HER2-negative, node-negative infiltrating ductal carcinoma. She received tamoxifen for three years, then began anastrozole, but three months later, a CT revealed hepatic metastases.
Track 4	Case from the practice of Dr Brenda L Towell A 54-year-old woman treated with mastectomy, dose-dense AC/paclitaxel, radiation therapy and tamoxifen three years ago for a three-centimeter, ER-positive, PR-negative, HER2-negative breast tumor with 11 positive nodes. A year later, she was switched to goserelin and anastrozole because of rising serum tumor markers and within a few weeks exhibited lymphangitic lung metastases.
Track 5	Case from the practice of Dr William G Reeves A 54-year-old woman who underwent a lumpectomy for a 2.3-cm, ER-positive, PR-positive, HER2-negative, moderately differentiated infiltrating ductal carcinoma with negative sentinel nodes and an Oncotype DX™ score of nine. She has been on anastrozole for the past 2.5 years.
Track 6	Case from the practice of Dr Sara M Garrido A 53-year-old woman with a history of hypertension and hyper-cholesterolemia who underwent a lumpectomy for a 0.8-cm, poorly differentiated, ER-negative, PR-negative, HER2-positive, node-negative, invasive ductal carcinoma with DCIS. She received six cycles of TCH followed by trastuzumab for a year.
Track 7	Case from the practice of Dr Margaret A Deutsch A 70-year-old woman who presented with a 1.8-cm, ER-positive, PR-negative, HER2-positive tumor. Refusing chemotherapy, she underwent radiation therapy and began anastrozole and trastuzumab.
Track 8	Case from the practice of Dr Atif M Hussein A 35-year-old woman with a five- to six-centimeter breast mass consisting of DCIS and high-grade, ER-positive (in 35 percent of cells), PR-negative (in less than one percent of cells), HER2-negative invasive tumor. She received four cycles of TAC and underwent mastectomy. Pathology revealed a 2.7-cm area of DCIS and 14 negative nodes.
Track 9	Case from the practice of Dr Stephen A Grabelsky A 57-year-old woman who underwent a modified radical mastectomy nine years ago for a 2.6-cm, ER-positive, PR-positive breast tumor with 2/12 positive nodes, followed by CMF and five years of tamoxifen. Two years later, she developed a chest wall recurrence.
Track 10	Case from the practice of Dr Deutsch A 47-year-old woman who presented with a 1.1-cm, triple-negative, invasive medullary breast cancer. Three years ago, she was treated with lumpectomy, radiation therapy and tamoxifen for DCIS. The patient has a strong family history of breast cancer, including her mother and two aunts.
Track 11	Case from the practice of Dr Lowell L Hart A 37-year-old mother of three who presented in the first trimester of pregnancy with a four- to five-centimeter, ER-positive, PR-negative, Grade III, HER2-amplified breast tumor. The pregnancy was terminated, and she received neoadjuvant TCH. At surgery, pathology revealed a 0.8-cm area of DCIS with 4/10 positive nodes.
Track 12	Case from the practice of Dr Allison A 44-year-old woman who presented with bilateral axillary nodes, which were ER-positive, PR-positive, HER2-positive breast carcinoma. Staging work-up revealed bone and liver metastases.